Gilead Sciences Revenue vs. Price To Book
| GILD34 Stock | BRL 287.56 4.47 1.58% |
For Gilead Sciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Gilead Sciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Gilead Sciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Gilead Sciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Gilead Sciences over time as well as its relative position and ranking within its peers.
Gilead |
Gilead Sciences Price To Book vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Gilead Sciences's current stock value. Our valuation model uses many indicators to compare Gilead Sciences value to that of its competitors to determine the firm's financial worth. Gilead Sciences is rated # 5 in revenue category among its peers. It is rated # 4 in price to book category among its peers . The ratio of Revenue to Price To Book for Gilead Sciences is about 5,145,610,925 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Gilead Sciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Gilead Sciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Gilead Revenue vs. Competition
Gilead Sciences is rated # 5 in revenue category among its peers. Market size based on revenue of Drug Manufacturers - Major industry is currently estimated at about 229.04 Billion. Gilead Sciences retains roughly 27.28 Billion in revenue claiming about 12% of equities under Drug Manufacturers - Major industry.
Gilead Price To Book vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Gilead Sciences |
| = | 27.28 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Gilead Sciences |
| = | 5.30 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Gilead Price To Book Comparison
Gilead Sciences is rated # 3 in price to book category among its peers.
Gilead Sciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Gilead Sciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Gilead Sciences will eventually generate negative long term returns. The profitability progress is the general direction of Gilead Sciences' change in net profit over the period of time. It can combine multiple indicators of Gilead Sciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 11000 people.
Gilead Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Gilead Sciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Gilead Sciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Gilead Sciences' important profitability drivers and their relationship over time.
Use Gilead Sciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Gilead Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gilead Sciences will appreciate offsetting losses from the drop in the long position's value.Gilead Sciences Pair Trading
Gilead Sciences Pair Trading Analysis
The ability to find closely correlated positions to Gilead Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Gilead Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Gilead Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Gilead Sciences to buy it.
The correlation of Gilead Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Gilead Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Gilead Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Gilead Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Gilead Sciences position
In addition to having Gilead Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cigarettes Thematic Idea Now
Cigarettes
Tobacco makers and distributors across globe. The Cigarettes theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cigarettes Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Gilead Stock
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
To fully project Gilead Sciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Gilead Sciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Gilead Sciences' income statement, its balance sheet, and the statement of cash flows.